nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—migraine—Prednisone—systemic scleroderma	0.685	1	CpDpCtD
Dihydroergotamine—ABCB1—Lisinopril—systemic scleroderma	0.0339	0.272	CbGbCtD
Dihydroergotamine—ABCB1—Captopril—systemic scleroderma	0.0254	0.203	CbGbCtD
Dihydroergotamine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.02	0.16	CbGbCtD
Dihydroergotamine—HTR2B—cardial valve—systemic scleroderma	0.0173	0.487	CbGeAlD
Dihydroergotamine—ABCB1—Prednisone—systemic scleroderma	0.016	0.128	CbGbCtD
Dihydroergotamine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.012	0.0959	CbGbCtD
Dihydroergotamine—CYP3A4—Prednisone—systemic scleroderma	0.00958	0.0767	CbGbCtD
Dihydroergotamine—ABCB1—Methotrexate—systemic scleroderma	0.00802	0.0642	CbGbCtD
Dihydroergotamine—HTR1B—artery—systemic scleroderma	0.00289	0.0811	CbGeAlD
Dihydroergotamine—HTR1D—artery—systemic scleroderma	0.00279	0.0785	CbGeAlD
Dihydroergotamine—HTR1B—blood vessel—systemic scleroderma	0.00225	0.0632	CbGeAlD
Dihydroergotamine—HTR1D—blood vessel—systemic scleroderma	0.00218	0.0612	CbGeAlD
Dihydroergotamine—HTR1D—connective tissue—systemic scleroderma	0.00112	0.0314	CbGeAlD
Dihydroergotamine—HTR2B—smooth muscle tissue—systemic scleroderma	0.00095	0.0267	CbGeAlD
Dihydroergotamine—HTR2B—skin of body—systemic scleroderma	0.000937	0.0264	CbGeAlD
Dihydroergotamine—HTR2B—digestive system—systemic scleroderma	0.00075	0.0211	CbGeAlD
Dihydroergotamine—HTR2B—tendon—systemic scleroderma	0.000714	0.0201	CbGeAlD
Dihydroergotamine—ABCB1—blood vessel—systemic scleroderma	0.000709	0.0199	CbGeAlD
Dihydroergotamine—ADRA2A—connective tissue—systemic scleroderma	0.000652	0.0183	CbGeAlD
Dihydroergotamine—HTR2B—lung—systemic scleroderma	0.000626	0.0176	CbGeAlD
Dihydroergotamine—ADRA2A—tendon—systemic scleroderma	0.000448	0.0126	CbGeAlD
Dihydroergotamine—ADRA2A—lung—systemic scleroderma	0.000393	0.0111	CbGeAlD
Dihydroergotamine—CYP3A4—digestive system—systemic scleroderma	0.000371	0.0104	CbGeAlD
Dihydroergotamine—ABCB1—digestive system—systemic scleroderma	0.000262	0.00738	CbGeAlD
Dihydroergotamine—Abdominal pain—Captopril—systemic scleroderma	0.000227	0.00147	CcSEcCtD
Dihydroergotamine—Body temperature increased—Captopril—systemic scleroderma	0.000227	0.00147	CcSEcCtD
Dihydroergotamine—Oedema—Mycophenolic acid—systemic scleroderma	0.000226	0.00146	CcSEcCtD
Dihydroergotamine—Anorexia—Leflunomide—systemic scleroderma	0.000225	0.00146	CcSEcCtD
Dihydroergotamine—Nausea—Pentoxifylline—systemic scleroderma	0.000225	0.00145	CcSEcCtD
Dihydroergotamine—Chills—Mycophenolate mofetil—systemic scleroderma	0.000225	0.00145	CcSEcCtD
Dihydroergotamine—Malaise—Lisinopril—systemic scleroderma	0.000224	0.00145	CcSEcCtD
Dihydroergotamine—Vertigo—Lisinopril—systemic scleroderma	0.000224	0.00145	CcSEcCtD
Dihydroergotamine—Diarrhoea—Mometasone—systemic scleroderma	0.000223	0.00144	CcSEcCtD
Dihydroergotamine—Shock—Mycophenolic acid—systemic scleroderma	0.000222	0.00143	CcSEcCtD
Dihydroergotamine—Hypotension—Leflunomide—systemic scleroderma	0.000221	0.00143	CcSEcCtD
Dihydroergotamine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00022	0.00142	CcSEcCtD
Dihydroergotamine—Palpitations—Lisinopril—systemic scleroderma	0.00022	0.00142	CcSEcCtD
Dihydroergotamine—ABCB1—lung—systemic scleroderma	0.000219	0.00616	CbGeAlD
Dihydroergotamine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000218	0.00141	CcSEcCtD
Dihydroergotamine—Muscular weakness—Prednisone—systemic scleroderma	0.000217	0.0014	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000215	0.00139	CcSEcCtD
Dihydroergotamine—Anorexia—Mycophenolic acid—systemic scleroderma	0.000215	0.00139	CcSEcCtD
Dihydroergotamine—Tension—Mycophenolate mofetil—systemic scleroderma	0.000214	0.00138	CcSEcCtD
Dihydroergotamine—Insomnia—Leflunomide—systemic scleroderma	0.000214	0.00138	CcSEcCtD
Dihydroergotamine—Paraesthesia—Leflunomide—systemic scleroderma	0.000212	0.00137	CcSEcCtD
Dihydroergotamine—Arthralgia—Lisinopril—systemic scleroderma	0.000212	0.00137	CcSEcCtD
Dihydroergotamine—Myalgia—Lisinopril—systemic scleroderma	0.000212	0.00137	CcSEcCtD
Dihydroergotamine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.000212	0.00137	CcSEcCtD
Dihydroergotamine—Anxiety—Lisinopril—systemic scleroderma	0.000211	0.00137	CcSEcCtD
Dihydroergotamine—Dyspnoea—Leflunomide—systemic scleroderma	0.000211	0.00136	CcSEcCtD
Dihydroergotamine—Hypotension—Mycophenolic acid—systemic scleroderma	0.000211	0.00136	CcSEcCtD
Dihydroergotamine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00021	0.00136	CcSEcCtD
Dihydroergotamine—Discomfort—Lisinopril—systemic scleroderma	0.000209	0.00135	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.000209	0.00135	CcSEcCtD
Dihydroergotamine—Dyspepsia—Leflunomide—systemic scleroderma	0.000208	0.00135	CcSEcCtD
Dihydroergotamine—Vomiting—Mometasone—systemic scleroderma	0.000208	0.00134	CcSEcCtD
Dihydroergotamine—Dry mouth—Lisinopril—systemic scleroderma	0.000207	0.00134	CcSEcCtD
Dihydroergotamine—Sweating increased—Prednisone—systemic scleroderma	0.000207	0.00134	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Azathioprine—systemic scleroderma	0.000206	0.00133	CcSEcCtD
Dihydroergotamine—Rash—Mometasone—systemic scleroderma	0.000206	0.00133	CcSEcCtD
Dihydroergotamine—Asthenia—Captopril—systemic scleroderma	0.000206	0.00133	CcSEcCtD
Dihydroergotamine—Dermatitis—Mometasone—systemic scleroderma	0.000206	0.00133	CcSEcCtD
Dihydroergotamine—Decreased appetite—Leflunomide—systemic scleroderma	0.000206	0.00133	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000205	0.00133	CcSEcCtD
Dihydroergotamine—Confusional state—Lisinopril—systemic scleroderma	0.000205	0.00132	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000205	0.00132	CcSEcCtD
Dihydroergotamine—Headache—Mometasone—systemic scleroderma	0.000205	0.00132	CcSEcCtD
Dihydroergotamine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000204	0.00132	CcSEcCtD
Dihydroergotamine—Insomnia—Mycophenolic acid—systemic scleroderma	0.000204	0.00132	CcSEcCtD
Dihydroergotamine—Fatigue—Leflunomide—systemic scleroderma	0.000204	0.00132	CcSEcCtD
Dihydroergotamine—Oedema—Lisinopril—systemic scleroderma	0.000203	0.00131	CcSEcCtD
Dihydroergotamine—Pruritus—Captopril—systemic scleroderma	0.000203	0.00131	CcSEcCtD
Dihydroergotamine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000203	0.00131	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000202	0.00131	CcSEcCtD
Dihydroergotamine—Pain—Leflunomide—systemic scleroderma	0.000202	0.00131	CcSEcCtD
Dihydroergotamine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000201	0.0013	CcSEcCtD
Dihydroergotamine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000201	0.0013	CcSEcCtD
Dihydroergotamine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.0002	0.0013	CcSEcCtD
Dihydroergotamine—Shock—Lisinopril—systemic scleroderma	0.0002	0.00129	CcSEcCtD
Dihydroergotamine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000199	0.00128	CcSEcCtD
Dihydroergotamine—Tachycardia—Lisinopril—systemic scleroderma	0.000198	0.00128	CcSEcCtD
Dihydroergotamine—Abdominal pain—Azathioprine—systemic scleroderma	0.000198	0.00128	CcSEcCtD
Dihydroergotamine—Body temperature increased—Azathioprine—systemic scleroderma	0.000198	0.00128	CcSEcCtD
Dihydroergotamine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000197	0.00127	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000196	0.00127	CcSEcCtD
Dihydroergotamine—Diarrhoea—Captopril—systemic scleroderma	0.000196	0.00127	CcSEcCtD
Dihydroergotamine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000196	0.00127	CcSEcCtD
Dihydroergotamine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000196	0.00127	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000195	0.00126	CcSEcCtD
Dihydroergotamine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000194	0.00126	CcSEcCtD
Dihydroergotamine—Nausea—Mometasone—systemic scleroderma	0.000194	0.00125	CcSEcCtD
Dihydroergotamine—Anorexia—Lisinopril—systemic scleroderma	0.000194	0.00125	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000193	0.00125	CcSEcCtD
Dihydroergotamine—Pain—Mycophenolic acid—systemic scleroderma	0.000193	0.00125	CcSEcCtD
Dihydroergotamine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000193	0.00125	CcSEcCtD
Dihydroergotamine—Hypotension—Lisinopril—systemic scleroderma	0.00019	0.00123	CcSEcCtD
Dihydroergotamine—Dizziness—Captopril—systemic scleroderma	0.00019	0.00123	CcSEcCtD
Dihydroergotamine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000188	0.00122	CcSEcCtD
Dihydroergotamine—Urticaria—Leflunomide—systemic scleroderma	0.000188	0.00121	CcSEcCtD
Dihydroergotamine—Abdominal pain—Leflunomide—systemic scleroderma	0.000187	0.00121	CcSEcCtD
Dihydroergotamine—Body temperature increased—Leflunomide—systemic scleroderma	0.000187	0.00121	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000186	0.00121	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000186	0.0012	CcSEcCtD
Dihydroergotamine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000186	0.0012	CcSEcCtD
Dihydroergotamine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000186	0.0012	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Prednisone—systemic scleroderma	0.000185	0.0012	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000185	0.0012	CcSEcCtD
Dihydroergotamine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000185	0.0012	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000184	0.00119	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000184	0.00119	CcSEcCtD
Dihydroergotamine—Insomnia—Lisinopril—systemic scleroderma	0.000184	0.00119	CcSEcCtD
Dihydroergotamine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000183	0.00119	CcSEcCtD
Dihydroergotamine—Paraesthesia—Lisinopril—systemic scleroderma	0.000182	0.00118	CcSEcCtD
Dihydroergotamine—Vomiting—Captopril—systemic scleroderma	0.000182	0.00118	CcSEcCtD
Dihydroergotamine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000182	0.00117	CcSEcCtD
Dihydroergotamine—Dyspnoea—Lisinopril—systemic scleroderma	0.000181	0.00117	CcSEcCtD
Dihydroergotamine—Rash—Captopril—systemic scleroderma	0.000181	0.00117	CcSEcCtD
Dihydroergotamine—Dermatitis—Captopril—systemic scleroderma	0.000181	0.00117	CcSEcCtD
Dihydroergotamine—Somnolence—Lisinopril—systemic scleroderma	0.000181	0.00117	CcSEcCtD
Dihydroergotamine—Headache—Captopril—systemic scleroderma	0.00018	0.00116	CcSEcCtD
Dihydroergotamine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000179	0.00116	CcSEcCtD
Dihydroergotamine—Dyspepsia—Lisinopril—systemic scleroderma	0.000179	0.00116	CcSEcCtD
Dihydroergotamine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000178	0.00115	CcSEcCtD
Dihydroergotamine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000178	0.00115	CcSEcCtD
Dihydroergotamine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000178	0.00115	CcSEcCtD
Dihydroergotamine—Decreased appetite—Lisinopril—systemic scleroderma	0.000177	0.00114	CcSEcCtD
Dihydroergotamine—Fatigue—Lisinopril—systemic scleroderma	0.000175	0.00113	CcSEcCtD
Dihydroergotamine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000175	0.00113	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000174	0.00113	CcSEcCtD
Dihydroergotamine—Pain—Lisinopril—systemic scleroderma	0.000174	0.00112	CcSEcCtD
Dihydroergotamine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000174	0.00112	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000172	0.00111	CcSEcCtD
Dihydroergotamine—Diarrhoea—Azathioprine—systemic scleroderma	0.000171	0.00111	CcSEcCtD
Dihydroergotamine—Nausea—Captopril—systemic scleroderma	0.00017	0.0011	CcSEcCtD
Dihydroergotamine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00017	0.0011	CcSEcCtD
Dihydroergotamine—Asthenia—Leflunomide—systemic scleroderma	0.00017	0.0011	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000167	0.00108	CcSEcCtD
Dihydroergotamine—Pruritus—Leflunomide—systemic scleroderma	0.000167	0.00108	CcSEcCtD
Dihydroergotamine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000166	0.00108	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000166	0.00107	CcSEcCtD
Dihydroergotamine—Dizziness—Azathioprine—systemic scleroderma	0.000166	0.00107	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000165	0.00107	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000162	0.00105	CcSEcCtD
Dihydroergotamine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000162	0.00105	CcSEcCtD
Dihydroergotamine—Diarrhoea—Leflunomide—systemic scleroderma	0.000162	0.00105	CcSEcCtD
Dihydroergotamine—Urticaria—Lisinopril—systemic scleroderma	0.000161	0.00104	CcSEcCtD
Dihydroergotamine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000161	0.00104	CcSEcCtD
Dihydroergotamine—Body temperature increased—Lisinopril—systemic scleroderma	0.000161	0.00104	CcSEcCtD
Dihydroergotamine—Abdominal pain—Lisinopril—systemic scleroderma	0.000161	0.00104	CcSEcCtD
Dihydroergotamine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00016	0.00103	CcSEcCtD
Dihydroergotamine—Pruritus—Mycophenolic acid—systemic scleroderma	0.00016	0.00103	CcSEcCtD
Dihydroergotamine—Vomiting—Azathioprine—systemic scleroderma	0.000159	0.00103	CcSEcCtD
Dihydroergotamine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000159	0.00103	CcSEcCtD
Dihydroergotamine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000158	0.00102	CcSEcCtD
Dihydroergotamine—Rash—Azathioprine—systemic scleroderma	0.000158	0.00102	CcSEcCtD
Dihydroergotamine—Dermatitis—Azathioprine—systemic scleroderma	0.000158	0.00102	CcSEcCtD
Dihydroergotamine—Flushing—Prednisone—systemic scleroderma	0.000158	0.00102	CcSEcCtD
Dihydroergotamine—Headache—Azathioprine—systemic scleroderma	0.000157	0.00101	CcSEcCtD
Dihydroergotamine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000157	0.00101	CcSEcCtD
Dihydroergotamine—Dizziness—Leflunomide—systemic scleroderma	0.000156	0.00101	CcSEcCtD
Dihydroergotamine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000155	0.001	CcSEcCtD
Dihydroergotamine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000154	0.000998	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Methotrexate—systemic scleroderma	0.000154	0.000994	CcSEcCtD
Dihydroergotamine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000984	CcSEcCtD
Dihydroergotamine—Vomiting—Leflunomide—systemic scleroderma	0.00015	0.000972	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Lisinopril—systemic scleroderma	0.00015	0.000968	CcSEcCtD
Dihydroergotamine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000149	0.000964	CcSEcCtD
Dihydroergotamine—Epistaxis—Methotrexate—systemic scleroderma	0.000149	0.000964	CcSEcCtD
Dihydroergotamine—Rash—Leflunomide—systemic scleroderma	0.000149	0.000964	CcSEcCtD
Dihydroergotamine—Dermatitis—Leflunomide—systemic scleroderma	0.000149	0.000963	CcSEcCtD
Dihydroergotamine—Nausea—Azathioprine—systemic scleroderma	0.000149	0.000961	CcSEcCtD
Dihydroergotamine—Headache—Leflunomide—systemic scleroderma	0.000148	0.000958	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000948	CcSEcCtD
Dihydroergotamine—Asthenia—Lisinopril—systemic scleroderma	0.000146	0.000942	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000941	CcSEcCtD
Dihydroergotamine—Pruritus—Lisinopril—systemic scleroderma	0.000144	0.000929	CcSEcCtD
Dihydroergotamine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000143	0.000927	CcSEcCtD
Dihydroergotamine—Rash—Mycophenolic acid—systemic scleroderma	0.000142	0.000919	CcSEcCtD
Dihydroergotamine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000142	0.000919	CcSEcCtD
Dihydroergotamine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000141	0.000914	CcSEcCtD
Dihydroergotamine—Headache—Mycophenolic acid—systemic scleroderma	0.000141	0.000914	CcSEcCtD
Dihydroergotamine—Pharyngitis—Methotrexate—systemic scleroderma	0.000141	0.000911	CcSEcCtD
Dihydroergotamine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000141	0.00091	CcSEcCtD
Dihydroergotamine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000141	0.00091	CcSEcCtD
Dihydroergotamine—Nausea—Leflunomide—systemic scleroderma	0.00014	0.000908	CcSEcCtD
Dihydroergotamine—Diarrhoea—Lisinopril—systemic scleroderma	0.000139	0.000899	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Prednisone—systemic scleroderma	0.000137	0.000887	CcSEcCtD
Dihydroergotamine—Visual impairment—Methotrexate—systemic scleroderma	0.000137	0.000884	CcSEcCtD
Dihydroergotamine—Agitation—Prednisone—systemic scleroderma	0.000136	0.000878	CcSEcCtD
Dihydroergotamine—Dizziness—Lisinopril—systemic scleroderma	0.000134	0.000869	CcSEcCtD
Dihydroergotamine—Nausea—Mycophenolic acid—systemic scleroderma	0.000134	0.000866	CcSEcCtD
Dihydroergotamine—Malaise—Prednisone—systemic scleroderma	0.000133	0.000862	CcSEcCtD
Dihydroergotamine—Vertigo—Prednisone—systemic scleroderma	0.000133	0.000859	CcSEcCtD
Dihydroergotamine—Tinnitus—Methotrexate—systemic scleroderma	0.000132	0.000856	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000848	CcSEcCtD
Dihydroergotamine—Vomiting—Lisinopril—systemic scleroderma	0.000129	0.000835	CcSEcCtD
Dihydroergotamine—Rash—Lisinopril—systemic scleroderma	0.000128	0.000828	CcSEcCtD
Dihydroergotamine—Dermatitis—Lisinopril—systemic scleroderma	0.000128	0.000827	CcSEcCtD
Dihydroergotamine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000826	CcSEcCtD
Dihydroergotamine—Hypertension—Prednisone—systemic scleroderma	0.000128	0.000825	CcSEcCtD
Dihydroergotamine—Chills—Methotrexate—systemic scleroderma	0.000127	0.000823	CcSEcCtD
Dihydroergotamine—Headache—Lisinopril—systemic scleroderma	0.000127	0.000823	CcSEcCtD
Dihydroergotamine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000814	CcSEcCtD
Dihydroergotamine—Arthralgia—Prednisone—systemic scleroderma	0.000126	0.000814	CcSEcCtD
Dihydroergotamine—Myalgia—Prednisone—systemic scleroderma	0.000126	0.000814	CcSEcCtD
Dihydroergotamine—Anxiety—Prednisone—systemic scleroderma	0.000125	0.000811	CcSEcCtD
Dihydroergotamine—Discomfort—Prednisone—systemic scleroderma	0.000124	0.000804	CcSEcCtD
Dihydroergotamine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000787	CcSEcCtD
Dihydroergotamine—Nausea—Lisinopril—systemic scleroderma	0.000121	0.00078	CcSEcCtD
Dihydroergotamine—Oedema—Prednisone—systemic scleroderma	0.000121	0.00078	CcSEcCtD
Dihydroergotamine—Shock—Prednisone—systemic scleroderma	0.000119	0.000768	CcSEcCtD
Dihydroergotamine—Tachycardia—Prednisone—systemic scleroderma	0.000118	0.000761	CcSEcCtD
Dihydroergotamine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000761	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000117	0.000754	CcSEcCtD
Dihydroergotamine—Anorexia—Prednisone—systemic scleroderma	0.000115	0.000744	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000115	0.000741	CcSEcCtD
Dihydroergotamine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000113	0.000732	CcSEcCtD
Dihydroergotamine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000726	CcSEcCtD
Dihydroergotamine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000725	CcSEcCtD
Dihydroergotamine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000721	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—systemic scleroderma	0.000111	0.00072	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—systemic scleroderma	0.000111	0.000718	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.00011	0.000711	CcSEcCtD
Dihydroergotamine—Insomnia—Prednisone—systemic scleroderma	0.000109	0.000706	CcSEcCtD
Dihydroergotamine—Paraesthesia—Prednisone—systemic scleroderma	0.000108	0.0007	CcSEcCtD
Dihydroergotamine—Dyspepsia—Prednisone—systemic scleroderma	0.000106	0.000687	CcSEcCtD
Dihydroergotamine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000684	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—systemic scleroderma	0.000105	0.00068	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—systemic scleroderma	0.000105	0.00068	CcSEcCtD
Dihydroergotamine—Decreased appetite—Prednisone—systemic scleroderma	0.000105	0.000678	CcSEcCtD
Dihydroergotamine—Fatigue—Prednisone—systemic scleroderma	0.000104	0.000673	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—systemic scleroderma	0.000104	0.000672	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—systemic scleroderma	0.000102	0.000657	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Prednisone—systemic scleroderma	9.94e-05	0.000643	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Prednisone—systemic scleroderma	9.87e-05	0.000638	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—systemic scleroderma	9.75e-05	0.00063	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—systemic scleroderma	9.61e-05	0.000621	CcSEcCtD
Dihydroergotamine—Urticaria—Prednisone—systemic scleroderma	9.58e-05	0.00062	CcSEcCtD
Dihydroergotamine—Abdominal pain—Prednisone—systemic scleroderma	9.54e-05	0.000617	CcSEcCtD
Dihydroergotamine—Body temperature increased—Prednisone—systemic scleroderma	9.54e-05	0.000617	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—systemic scleroderma	9.42e-05	0.000609	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.19e-05	0.000594	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—systemic scleroderma	9.12e-05	0.00059	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—systemic scleroderma	9.05e-05	0.000585	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—systemic scleroderma	8.99e-05	0.000581	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—systemic scleroderma	8.96e-05	0.00058	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Prednisone—systemic scleroderma	8.89e-05	0.000575	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—systemic scleroderma	8.88e-05	0.000574	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—systemic scleroderma	8.77e-05	0.000567	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—systemic scleroderma	8.69e-05	0.000562	CcSEcCtD
Dihydroergotamine—Asthenia—Prednisone—systemic scleroderma	8.66e-05	0.00056	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—systemic scleroderma	8.62e-05	0.000558	CcSEcCtD
Dihydroergotamine—Pruritus—Prednisone—systemic scleroderma	8.54e-05	0.000552	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—systemic scleroderma	8.31e-05	0.000537	CcSEcCtD
Dihydroergotamine—Diarrhoea—Prednisone—systemic scleroderma	8.26e-05	0.000534	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.25e-05	0.000533	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—systemic scleroderma	8.01e-05	0.000518	CcSEcCtD
Dihydroergotamine—Dizziness—Prednisone—systemic scleroderma	7.98e-05	0.000516	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—systemic scleroderma	7.97e-05	0.000515	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—systemic scleroderma	7.97e-05	0.000515	CcSEcCtD
Dihydroergotamine—Vomiting—Prednisone—systemic scleroderma	7.67e-05	0.000496	CcSEcCtD
Dihydroergotamine—Rash—Prednisone—systemic scleroderma	7.61e-05	0.000492	CcSEcCtD
Dihydroergotamine—Dermatitis—Prednisone—systemic scleroderma	7.6e-05	0.000491	CcSEcCtD
Dihydroergotamine—Headache—Prednisone—systemic scleroderma	7.56e-05	0.000489	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—systemic scleroderma	7.43e-05	0.00048	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—systemic scleroderma	7.23e-05	0.000468	CcSEcCtD
Dihydroergotamine—Nausea—Prednisone—systemic scleroderma	7.17e-05	0.000463	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—systemic scleroderma	7.13e-05	0.000461	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—systemic scleroderma	6.9e-05	0.000446	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—systemic scleroderma	6.67e-05	0.000431	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—systemic scleroderma	6.41e-05	0.000415	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—systemic scleroderma	6.36e-05	0.000411	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—systemic scleroderma	6.35e-05	0.000411	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—systemic scleroderma	6.32e-05	0.000408	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—systemic scleroderma	5.99e-05	0.000387	CcSEcCtD
